Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 809 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Got the COVID Blues? August 12, 2020 EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 Helping Kids Cope With Cancer: “Your Stories” Podcast January 11, 2021 Spotlight On: Occupational Therapists in Cancer Care November 4, 2021 Load more HOT NEWS Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint... How do we die of cancer? What we know (and what... European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025 HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for...
